{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:01Z","timestamp":1789549561485,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.msard.2023.105400","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T12:19:42Z","timestamp":1703247582000},"page":"105400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-8711","authenticated-orcid":false,"given":"David","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angray S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105400_bib0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ced.13726","article-title":"Early-onset neutropenia after rituximab therapy for bullous pemphigoid","volume":"44","author":"Adler","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.msard.2023.105400_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105400_bib0004","article-title":"Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis","author":"Alvarez","year":"2022","journal-title":"ACTRIMS"},{"key":"10.1016\/j.msard.2023.105400_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-immunol-020711-074942","article-title":"Neutrophil function: from mechanisms to disease","volume":"30","author":"Amulic","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0006","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/HAB-210453","article-title":"Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis","volume":"29","author":"Baker","year":"2021","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.msard.2023.105400_bib0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.msard.2017.09.028","article-title":"Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment","volume":"18","author":"Baker","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0010","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105400_bib0011","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578136","article-title":"Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases","volume":"381","author":"Balazs","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105400_bib0016","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105400_bib0017","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/imr.13159","article-title":"Neutrophils as immune effector cells in antibody therapy in cancer","volume":"314","author":"Behrens","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.msard.2023.105400_bib0018","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.immuni.2021.06.006","article-title":"The neutrophil","volume":"54","author":"Burn","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.msard.2023.105400_bib0019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/meth.1996.0398","article-title":"B-cell-derived granulocyte-colony stimulating factor (G-CSF)","volume":"11","author":"Corcione","year":"1997","journal-title":"Methods"},{"key":"10.1016\/j.msard.2023.105400_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105400_bib0022","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1182\/blood-2015-02-629444","article-title":"Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice","volume":"125","author":"Day","year":"2015","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.msard.2023.105400_bib0023","doi-asserted-by":"crossref","first-page":"e12949","DOI":"10.1111\/eci.12949","article-title":"CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease","volume":"48","author":"De Filippo","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.msard.2023.105400_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.105400_bib0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.msard.2023.105400_bib0026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1074-7613(01)00185-6","article-title":"The earliest stages of B cell development require a chemokine stromal cell-derived factor\/pre-B cell growth-stimulating factor","volume":"15","author":"Egawa","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.msard.2023.105400_bib0027","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS","volume":"8","author":"Fern\u00e1ndez-Velasco","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105400_bib0028","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstr\u00f6m's macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.msard.2023.105400_bib0029","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaneurol.2017.1456","article-title":"Neutropenia in patients with multiple sclerosis treated with alemtuzumab","volume":"74","author":"Gait\u00e1n","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105400_bib0030","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-019-0521-4","article-title":"GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis","volume":"25","author":"Galli","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1176\/jnp.8.2.194","article-title":"Conditioning of cyclophosphamide-induced leukopenia in humans","volume":"8","author":"Giang","year":"1996","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.msard.2023.105400_bib0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0b013e3283414edf","article-title":"Neutropenia associated with rituximab therapy","volume":"18","author":"Grant","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.msard.2023.105400_bib0033","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/pgs-2015-0008","article-title":"Pharmacokinetics and pharmacogenomics of \u03b2-lactam-induced neutropenia","volume":"17","author":"Hahn","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2023.105400_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA adverse event reporting system (FAERS)","volume":"65","author":"Hammer","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0035","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2020.00594","article-title":"Expansion of neutrophils and classical and nonclassical monocytes as a hallmark in relapsing-remitting multiple sclerosis","volume":"11","author":"Haschka","year":"2020","journal-title":"Front. Immunol."},{"issue":"18 Supplement","key":"10.1016\/j.msard.2023.105400_bib0036","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1212\/WNL.98.18_supplement.2481","article-title":"Long-term safety of ofatumumab in patients with relapsing multiple sclerosis (S14.004)","volume":"98","author":"Hauser","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105400_bib0037","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105400_bib0038","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1352458515586084","article-title":"Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica","volume":"22","author":"Hertwig","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105400_bib0039","first-page":"1","article-title":"Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?","volume":"9","author":"Hess","year":"2023","journal-title":"Nervenarzt"},{"key":"10.1016\/j.msard.2023.105400_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European vasculitis study group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2169\/internalmedicine.42.102","article-title":"Autoimmune neutropenia associated with multiple sclerosis","volume":"42","author":"Kozuka","year":"2003","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0042","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0043","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Bar-Or A; Canadian B cells in MS Team. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.msard.2023.105400_bib0044","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5581\/1516-8484.20130009","article-title":"Neutropenic patients and their infectious complications at a University Hospital","volume":"35","author":"Lima","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.msard.2023.105400_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105400_bib0046","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/1471-2164-14-632","article-title":"An expression atlas of human primary cells: inference of gene function from coexpression networks","volume":"14","author":"Mabbott","year":"2013","journal-title":"BMB Genom."},{"key":"10.1016\/j.msard.2023.105400_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-62703-845-4_1","article-title":"The role of neutrophils in the immune system: an overview","volume":"1124","author":"Malech","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.msard.2023.105400_bib0048","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2023.105400_bib0049","first-page":"765","article-title":"Drug-Induced Neutropenia: a Focus on rituximab-induced late-onset neutropenia","volume":"41","author":"Moore","year":"2016","journal-title":"Pharm. Therapeut."},{"key":"10.1016\/j.msard.2023.105400_bib0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/ewjm.172.4.248","article-title":"Severe neutropenia: a diagnostic approach","volume":"172","author":"Munshi","year":"2000","journal-title":"West J. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0051","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.leukres.2009.10.029","article-title":"Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils","volume":"34","author":"Nakagawa","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.msard.2023.105400_bib0052","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jcyt.2023.02.006","article-title":"Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study","volume":"25","author":"Nakamura","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.msard.2023.105400_bib0053","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/152.1.90","article-title":"Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics","volume":"152","author":"Neftel","year":"1985","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2023.105400_bib0054","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B cell depletion therapy in MS according to memory B cell monitoring","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105400_bib0055","doi-asserted-by":"crossref","first-page":"eabi4632","DOI":"10.1126\/scitranslmed.abi4632","article-title":"Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity","volume":"14","author":"Ochs","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0057","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0058","article-title":"Neutropaenia complications from ocrelizumab and rituximab treatment","volume":"81","author":"Pang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.msard.2023.105400_bib0061","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Audoin B. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105400_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0063","doi-asserted-by":"crossref","first-page":"e05299","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropania induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.msard.2023.105400_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103931","article-title":"Immunological consequences of cladribine treatment in multiple sclerosis: a real-world study","volume":"64","author":"Rolfes","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types?","volume":"9","author":"Rosales","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.msard.2023.105400_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104090","article-title":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: a retrospective case series and a systematic review of reported cases","volume":"68","author":"Rossi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105400_bib0067","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","article-title":"Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"44","author":"Saidha","year":"2023","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2023.105400_bib0068","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med"},{"issue":"Suppl 5","key":"10.1016\/j.msard.2023.105400_bib0069","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1098-3597(06)80053-0","article-title":"Neutropenia: etiology and pathogenesis","volume":"8","author":"Schwartzberg","year":"2006","journal-title":"Clin. Cornerstone"},{"key":"10.1016\/j.msard.2023.105400_bib0070","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Cree BAC; ULTIMATE I and ULTIMATE II investigators. Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0071","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fimmu.2018.01672","article-title":"Mass cytometry for the assessment of immune reconstitution after hematopoietic stem cell transplantation","volume":"9","author":"Stern","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.105400_bib0072","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.msard.2023.105400_bib0001","unstructured":"Uplizna\u00ae. 2023. Summary of product characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/uplizna-epar-public-assessment-report_en.pdf (accessed 5 December 2023)."},{"key":"10.1016\/j.msard.2023.105400_bib0073","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12883-018-1183-4","article-title":"A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes","volume":"18","author":"Vakrakou","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.105400_bib0074","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2016-08-735605","article-title":"Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies","volume":"129","author":"Valgardsdottir","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.msard.2023.105400_bib0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2402424","article-title":"Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils","volume":"16","author":"van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.msard.2023.105400_bib0076","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105400_bib0077","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-019-0260-2","article-title":"Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study","volume":"9","author":"van Oers","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.msard.2023.105400_bib0078","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2021005367","article-title":"Sodium stibogluconate and CD47-SIRP\u03b1 blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing","volume":"6","author":"van Rees","year":"2022","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.msard.2023.105400_bib0079","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105400_bib0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","article-title":"Immunoglobulin G Fc receptor FcgammaRIIIa 158V\/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma","volume":"28","author":"Weng","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2023.105400_bib0081","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/gb-2009-10-11-r130","article-title":"BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources","volume":"10","author":"Wu","year":"2009","journal-title":"Genome Biol."},{"key":"10.1016\/j.msard.2023.105400_bib0082","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.msard.2018.04.014","article-title":"Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion","volume":"23","author":"Yiannopoulou","year":"2018","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:49Z","timestamp":1761901669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823008994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":81,"alternative-id":["S2211034823008994"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105400","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105400"}}